Related Experiment Video

Updated: Sep 5, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K

Novel Insights into Factor D Inhibition

Eleni Gavriilaki1, Anna Papakonstantinou2, Konstantinos A Agrios3

  • 1Hematology Department, G Papanicolaou Hospital, 57010 Thessaloniki, Greece.

International Journal of Molecular Sciences
|July 9, 2022
PubMed

Insights

Factor D inhibition offers a promising therapeutic strategy for complement-mediated diseases, including Paroxysmal nocturnal hemoglobinuria (PNH) and others. Further research is needed to explore its safety and efficacy across various complementopathies.

Area of Science:

  • Medical Specialties
  • Immunology
  • Pharmacology

Background:

  • Complement-mediated diseases (complementopathies) like PNH, CAD, and TA-TMA require advanced diagnostics and therapeutics.
  • Current complement inhibitors, often orphan drugs, have improved outcomes but face challenges.
  • Upstream inhibition shows efficacy in PNH, but broader application needs further study.

Purpose of the Study:

  • To review novel insights into factor D inhibition for complementopathies.
  • To highlight unmet clinical needs in complementopathy treatment.
  • To explore factor D inhibition as a promising therapeutic target.

Main Methods:

  • Narrative review of current literature.
  • Analysis of complement inhibitor mechanisms and clinical data.
  • Exploration of factor D inhibition as a therapeutic strategy.

Main Results:

  • Factor D inhibition is identified as a promising upstream target.
  • Current upstream inhibition strategies show significant efficacy in PNH.
  • Further studies are required to establish safety and efficacy in other complementopathies.

Conclusions:

  • Factor D inhibition presents a novel therapeutic avenue for complementopathies.
  • Addressing cost and availability issues is crucial for treatment accessibility.
  • Continued research into upstream inhibition is warranted for broader clinical application.

Keywords:
complementfactor Dparoxysmal nocturnal hemoglobinuria

More Related Videos

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.3K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.4K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
248
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
185
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
879
Factors Affecting Activity Coefficient01:17

Factors Affecting Activity Coefficient

The extended Debye-Hückel equation indicates that the activity coefficient of an ion in an aqueous solution at 25°C depends on three partially interdependent properties: the ionic strength of the solution, the charge of the ion, and the ion size. 
The activity coefficient value for an ion is close to one when the solution has almost zero ionic strength, i.e., when the solution shows close to ideal behavior. As the ionic strength of the solution increases from 0 to 0.1 mol/L, a...
907